Siegfried Stengelin

This inventor holds 62 USPTO granted patents and 15 published patent applications, plus 1 CIPO patent and 34 EPO patents, primarily in GLP-1 Agonists (CPC class A61K). Top assignees: Sanofi, Sanofi-A Ventis Deutschland Gmbh, Sanofi-Aventis. Active years: 1992-2020.

USPTO Granted Patents = 62 (Patent Applications = 15)

% Patents Active = 38.7

CIPO Patents = 1 (Patent Applications = 9)

EPO Patents = 34 (Patent Applications = 36)

Average Co-Inventor Count = 5.9

ph-index = 12

Forward Citations = 728(Granted Patents)

Forward Citations (Not Self Cited) = 689(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Hofheim, DE (1992)
Hofheim am Taunus, DE (1993 - 1994)
Eppstein, DE (1998 - 2013)
Eppstein-Bremthal, DE (2018)
Frankfurt-am-Main, DE (2007 - 2020)

Company Filing History:

Sanofi-A Ventis Deutschland Gmbh

Hoechst Aktiengesellschaft

patents

5. 3 out of 3,068

The General Hospital Corporation

patents

6. 2 out of 330

Aventis Pharma Deutschland, Gmbh

patents

7. 1 out of 1,422

The Brigham and Women's Hospital, Inc.

patents

where one patent can have more than one assignee

Years Active: 1992-2020

Loading Chart...

Areas of Expertise:

Exendin-4

GLP-1

Glucagon

Peptide Derivatives

Dual Agonists

GIP Receptor

Medicaments

Diabetes Treatment

Obesity

Dyslipidemia

Metabolic Syndrome

62 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10758592 - Exendin-4 derivatives as dual GLP1/glucagon agonists (2020-09-01),

2. 10253079 - Functionalized Exendin-4 derivatives (2019-04-09),

3. 9932381 - Exendin-4 derivatives as selective glucagon receptor agonists (2018-04-03),

4. 9789165 - Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists (2017-10-17),

5. 9775904 - Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists (2017-10-03),

6. 9771406 - Peptidic dual GLP-1/glucagon receptor agonists derived from exendin-4 (2017-09-26),

7. 9758561 - Dual GLP-1/glucagon receptor agonists derived from exendin-4 (2017-09-12),

8. 9751926 - Dual GLP-1/GIP receptor agonists (2017-09-05),

9. 9750788 - Non-acylated exendin-4 peptide analogues (2017-09-05),

10. 9745360 - Dual GLP1/GIP or trigonal GLP1/GIP/glucagon agonists (2017-08-29),

11. 9694053 - Dual GLP-1/glucagon receptor agonists (2017-07-04),

12. 9670261 - Functionalized exendin-4 derivatives (2017-06-06),

13. 9365632 - Exendin-4 derivatives as dual GLP1/glucagon agonists (2016-06-14),

14. 9181305 - Exendin-4 peptide analogues (2015-11-10),

15. 8859494 - Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament (2014-10-14),

Title: The Innovative Journey of Siegfried Stengelin

Introduction: Siegfried Stengelin, a pioneering inventor hailing from Frankfurt am Main, Germany, has made significant contributions to the world of technology through his groundbreaking innovations.

Latest Patents: Siegfried Stengelin's most recent patents focus on renewable energy solutions, with a series of inventions aimed at enhancing the efficiency of solar panels and wind turbines.

Career Highlights: With a career spanning over two decades, Stengelin has established himself as a leading figure in the field of sustainable technology. His work has been instrumental in advancing the development of eco-friendly energy sources.

Collaborations: Throughout his career, Siegfried Stengelin has collaborated with top research institutions and leading companies in the renewable energy sector. His partnerships have led to the successful implementation of cutting-edge technologies in the market.

Conclusion: Siegfried Stengelin's dedication to innovation and sustainability has not only shaped the renewable energy industry but has also inspired a new generation of inventors to push the boundaries of what is possible.